The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
Great news for PVR. The site survey has passed the EIA assessment and ready to be rubber stamped by DCCAEhttps://www.dccae.gov.ie/en-ie/natural-resources/consultations/Pages/Public-Consultation-for-site-survey-at-Barryroe-North-Celtic-Sea-Exola-DAC.aspx
You’re completely right, my apologies! Forgot to factor 80% of the licence owned. It’s 346Mmboe though.
Therefore, that equates to 32p/ps for our 80%!
hoper, again you’re correct with SLE’s NPI. I wasn’t factoring that in for the simple calculation of 2C resources at this stage but if you were to do so, we’d be looking at 30.56p/ps.
Not bad when current sp is 3.875p!
Looked like a rollover to me
$3/bbl is the conservative benchmark set in the North Sea for valuing 2C resources. That equates to £339M or 40p/ps! Current sp... 3.75p!
Few notes if anyone is interested:
https://twitter.com/aim_bagger/status/1274682913800491014?s=21
I reckon Blackrock have about 4M left after today, hopefully just one more day of churn needed to clear them. They may have the rest taken off their hands by another fund.
500k buy at 16p, someone’s not messing around! £80k...
“C4XD’s focus on diseases with high unmet medical need is entirely in line with our objective of ensuring that innovative life sciences technologies progress along their development pathway towards the patients who so desperately need them.”
https://www.lifearc.org/news/2018/lifearc-and-c4x/
Looking good today. Breaking out on the chart
Huge news today, well off the radar at the moment. Big day coming.
"Specifically, one stage IV NSCLC patient had received seven lines of therapy over nearly three years with little response. In this patient the combination of MRx0518 + KEYTRUDA achieved an overall 51% reduction in target tumors at last assessment."
https://www.newkerala.com/news/2020/62544.htm#.XpsBoPaoH1o.twitter
The more I’m reading the more I’m loving this company! The collaboration agreement with Merck is sensational and with them taking a 7% stake in the coming in the recent placing it would suggest they are very happy with data to date! If just one of the upfront cash payments land then the sp will rerate overnight from these levels.
Under the terms of the agreement 4D's proprietary MicroRx(R) platform will be paired with MSD's expertise in the development and commercialisation of novel vaccines, to discover and develop LBPs as vaccines in up to three undisclosed indications. 4D has the right, subject to certain conditions, to cause MSD to purchase $5 million in ordinary shares in 4D during the first 12 months of the collaboration. In addition to an upfront cash payment, for each indication, 4D will be eligible to receive up to $347.5 million in option exercise and development and regulatory milestone payments, plus tiered royalties on annual net sales of any licensed products derived from the collaboration. MSD will be responsible for development, manufacturing and commercialisation following the exercise of any of its exclusive options.
It’s worth noting Peter that the fund recently raised at 50p are likely to last the company at least 8-9 months as they initially sought to raise £18M and ended up with £22M due to it being massively oversubscribed. Gives the company more time if required and better bargaining power when looking for a licensing partner. Obviously Merck would make complete sense and they already have a collaboration agreement in place with them. Interesting times!
Wonder if 4D are assisting MSD with this?
https://pharmaphorum.com/?p=65789
Gone unnoticed this one...
Merck will pay the microbiome company 4D Pharma up to €316.5M to develop vaccines!
24M Mcap...
https://t.co/GF4jWF6QhZ
MM’s **** up shop on the drop, cannot buy at advertised ask, NT. IG want 1.4249 for just £500, bounces from here IMO. Cash v Mcap cannot be ignored.
£7.8M cash as of 29th March
No debt
£3.8M Mcap!
55% reduction in cash burn
Breakeven at operating level for 1st time
Current sp 50% of cash balance
Company priced in for free
Should be double the current sp just to get near cash level...
If people read the RNS’ properly they will see that the co. were always looking to take more ASLR, originally at 0.4p but they managed to do it at 0.5p. It’s clear to see the placings are a way of allowing Akers and his crew to buy big chunks of stock ahead of the grand plan.
If the co. didn’t do the placings then they wouldn’t have been able to take the stock they have done at 0.2 & 0.5p. This has all the hallmarks of an ASLR, check out the early days at YOLO, huge similarities.
There doesn’t seem to be plans for another placing either. 3x TR1’s to come Monday/Tuesday next week after the shares have been admitted on 3rd.
In addition to the above it’s saved the company from issuing a further 87M shares by being able to get the placing away at 0.5p and they’ve agreed to take the ASLR warrants off Akers hands at 70p when it was originally going to be 85p. Winner all round.
I don’t see it that way. It’s been used as a vehicle to get Akers and his mates in, if they didn’t do the placings then they wouldn’t have been able to take the stock they have done at 0.2 & 0.5p. This has all the hallmarks of an ASLR, check out the early days at YOLO, huge similarities. Also there doesn’t seem to be plans for another placing, as was outlined in the first investment RNS they were going to take more ASLR, originally at 0.4p but they’ve managed to do it at 0.5p. 3x TR1’s to come Friday/Monday.
Plus if you read further down the RNS 2x companies (likely Akers mates) have taken big stakes, only 70M shares to flush which was Friday’s volume alone!
70,000,000 Consideration Shares, which will represent 10.14% of the Company's enlarged share capital on Admission, are to be issued to certain clients of Optiva Securities Limited. 56,000,000 Consideration Shares, which will represent 8.12% of the Company's enlarged share capital on Admission, are to be issued to certain clients of Peregrine & Black Investment Management Limited. 42,000,000 Consideration Shares, which will represent 6.09% of the Company's enlarged share capital on Admission, are to be issued to certain clients of Intrinsic Capital LLP.